FAQ

FAQ published on July 24, 2017
Dr. Stephen Ansell explains the mechanism of action and the role of immune checkpoint inhibitors in patients with classical Hodgkin lymphoma.
FAQ published on June 19, 2017
Dr. Stephen Ansell explains the mechanism of action and the role of immune checkpoint inhibitors in patients with classical Hodgkin lymphoma.
FAQ published on June 7, 2017
Join Dr. Ansell as he discusses the new PD-1 blocking antibodies that are showing response in HL patients post-transplant.
FAQ published on December 7, 2016
Join Dr. Paul Bröckelmann as he discusses where nivolumab fits in treating patients with classical Hodgkin lymphoma.
FAQ published on November 2, 2016
Join Dr. Paul Bröckelmann as he discusses treatment options for HL patients who are at risk for relapse or disease progression after transplant.
FAQ published on October 5, 2016
Join Dr. Paul Bröckelmann as he discusses how to identity HL patients who are at risk for relapse or disease progression after transplant.
FAQ published on September 6, 2016
Join Dr. Robert Chen as he discusses new and emerging treatments in HL that are most likely to have the greatest impact on improving outcomes for relapsed or refractory disease.
FAQ published on August 4, 2016
Join Dr. Andrew Evens as he explains the relative roles of immunohistochemical studies versus flow cytometry results in the accurate diagnosis and assessment of patients with Hodgkin lymphoma.
FAQ published on July 7, 2016
Join Dr. Robert Chen as he discusses which treatment approaches may increase the potential for a higher cure rate in patients with relapsed or refractory Hodgkin lymphoma.
FAQ published on June 1, 2016
In this Managing Hodgkin Lymphoma FAQ, join Dr. Andrew Evens as he explains when it is appropriate and/or necessary to utilize mRNA testing in the diagnosis and staging of Hodgkin lymphoma (HL).
Page 2 of 7
Results 11 - 20 of 62

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved